Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H2 2017’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

AIMM Therapeutics BV

Aphios Corp

BioCryst Pharmaceuticals Inc

BiondVax Pharmaceuticals Ltd

Cadila Healthcare Ltd

Celltrion Inc

FluGen Inc

Glide Pharmaceutical Technologies Ltd

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

MedImmune LLC

Mucosis BV

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Protein Sciences Corp

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

VBI Vaccines Inc

Visterra Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Influenza A Virus, H3N2 Subtype Infections - Overview 8

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 18

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Adimmune Corp 28

AIMM Therapeutics BV 28

Aphios Corp 29

BioCryst Pharmaceuticals Inc 29

BiondVax Pharmaceuticals Ltd 30

Cadila Healthcare Ltd 30

Celltrion Inc 31

FluGen Inc 31

Glide Pharmaceutical Technologies Ltd 32

Inovio Pharmaceuticals Inc 32

Jiangsu Kanion Pharmaceutical Co Ltd 33

Johnson & Johnson 33

Medicago Inc 34

MedImmune LLC 34

Mucosis BV 35

NanoViricides Inc 35

Novavax Inc 36

OPKO Health Inc 36

Protein Sciences Corp 37

Sanofi Pasteur SA 38

Sarepta Therapeutics Inc 38

SK Chemicals Co Ltd 39

Takeda Pharmaceutical Company Ltd 39

VBI Vaccines Inc 40

Visterra Inc 40

Influenza A Virus, H3N2 Subtype Infections - Drug Profiles 41

APP-0205 - Drug Profile 41

APP-309 - Drug Profile 42

Aspidasept - Drug Profile 43

AT-0701 - Drug Profile 44

AV-5075S - Drug Profile 45

AV-5080 - Drug Profile 46

C-05 - Drug Profile 47

cetylpyridinium chloride - Drug Profile 48

CR-8043 - Drug Profile 49

CTP-27 - Drug Profile 50

Fluad (quadrivalent) - Drug Profile 51

Gamma-Flu - Drug Profile 52

influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 53

influenza [strain A/H3N2] vaccine - Drug Profile 54

influenza [strain A/H3N2] vaccine - Drug Profile 55

influenza [strain A/H3N2] vaccine - Drug Profile 56

influenza [strain A/H3N2v] vaccine - Drug Profile 57

influenza [strain A/H3N2v] vaccine - Drug Profile 58

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 59

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 60

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 61

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 62

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 63

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 64

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 67

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 68

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 69

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 70

influenza [strains A/H1N1 + A/H3N2 + B] (split virion) vaccine - Drug Profile 71

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 72

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 76

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 77

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 78

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 79

influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile 80

influenza [strains A/H3N2 + A/H1N1] vaccine - Drug Profile 81

M-001 - Drug Profile 82

NBP-607 - Drug Profile 88

NEO-8877 - Drug Profile 89

NVINF-1 - Drug Profile 90

NVINF-2 - Drug Profile 95

Peptides for Influenza Infections - Drug Profile 98

peramivir - Drug Profile 99

pertussis [strain BPZE1] vaccine - Drug Profile 101

pimodivir hydrochloride - Drug Profile 103

PNSIA-28 - Drug Profile 106

radavirsen - Drug Profile 107

REDEE FLU - Drug Profile 109

Small Molecules for RSV and Influenza A Infections - Drug Profile 110

Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile 111

VIS-410 - Drug Profile 112

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 115

Influenza A Virus, H3N2 Subtype Infections - Discontinued Products 116

Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 117

Featured News & Press Releases 117

Appendix 123

Methodology 123

Coverage 123

Secondary Research 123

Primary Research 123

Expert Panel Validation 123

Contact Us 123

Disclaimer 124

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AIMM Therapeutics BV, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cadila Healthcare Ltd, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Glide Pharmaceutical Technologies Ltd, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Johnson & Johnson, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by MedImmune LLC, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Mucosis BV, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by OPKO Health Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Protein Sciences Corp, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi Pasteur SA, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sarepta Therapeutics Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by SK Chemicals Co Ltd, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by VBI Vaccines Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Visterra Inc, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, H2 2017

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports